Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 9/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333967 | 0.93 | HTR1A (0.44) | LTA4HTMEM97SIGMAR1 | |
| SCHEMBL2157360 | 0.84 | SLC6A4 (0.48) | LTA4HTMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2157274 | 0.83 | SLC6A4 (0.48) | LTA4HTMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2158456 | 0.83 | KCNA5 (0.45) | ALDH1A1LTA4HTMEM97SIGMAR1KCNA5 | |
| Hydrochloric Acid SCHEMBL2157331 | 0.74 | KCNA5 (0.48) | ALDH1A1PKMLTA4HTMEM97SIGMAR1 | |
| SCHEMBL1299631 | 0.74 | SIGMAR1 (0.52) | ALDH1A1SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL1299136 | 0.73 | SIGMAR1 (0.51) | ALDH1A1SIGMAR1MEN1KMT2A | |
| SCHEMBL3208887 | 0.73 | MIF (0.37) | ALDH1A1PKMSIGMAR1TDP1MEN1 | |
| SCHEMBL2157136 | 0.71 | SLC6A3 (0.47) | — | |
| SCHEMBL938718 | 0.70 | EPHX1 (0.37) | ALDH1A1PKMSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281890-A1 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION | 2011-11-17 | — | — | US | claimed |
| EP-1978959-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2011-11-09 | — | — | EP | claimed |
| US-8183374-B2 | Piperidine and piperazine derivatives | M'S SCIENCE CORPORATION (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-2340835-A1 | Piperidine and piperazine derivatives | M's Science Corporation (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-1976525-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES | MS SCIENCE CORP (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | AGY THERAPEUTICS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SUN CONNIE L | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137334-A1 | Piperidine and Piperazine Derivatives | SIGMAR1, OPRM1, OPRD1 | ALDH1A1 509/4885PKM 1124/4885LTA4H 2934/4885 |
| US-20110281890-A1 | Piperidine and piperazine derivatives | SIGMAR1, OPRM1, OPRD1 | ALDH1A1 1025/4885PKM 762/4885LTA4H 3597/4885 |
| US-20100256162-A1 | Piperazine and Piperidine Derivatives | SIGMAR1, OPRM1, OPRD1 | ALDH1A1 1035/4885PKM 750/4885LTA4H 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.